December 29, 2025

Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision

For postmenopausal women with HR-positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider ...

The ASCO Post

December 29, 2025

OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer

For women with high-risk, BRCA-positive breast cancer, 1 year of adjuvant treatment with the PARP inhibitor olaparib following primary treatment continued to improve overall survival compared with pla...

The ASCO Post

December 18, 2025

10-Year Outcomes With Adjuvant Metronomic Capecitabine in Early Triple-Negative Breast Cancer

In a 10-year update of a Chinese phase III trial (SYSUCC-001) reported in The Lancet Oncology, Yuan et al found that the sequential addition of metronomic capecitabine to standard adjuvant therapy con...

The ASCO Post

December 17, 2025

Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction

Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treat...

The ASCO Post

December 15, 2025

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.

Dana-Farber

December 15, 2025

AI Models Advance Individualized Breast Cancer Recurrence Risk Assessments

Two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) highlighted new artificial intelligence (AI) tools and systems for improving distant recurrence risk stratification in early b...

The ASCO Post

December 12, 2025

Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer

Adding the selective HER2 inhibitor tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, pot...

The ASCO Post

December 12, 2025

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?

Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's ris...

The ASCO Post

December 11, 2025

Large AI Breast Cancer Screening Trial Increases Detection Rate by 20%

Using an artificial intelligence (AI)–integrated workflow, DeepHealth, computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more breast cancer cases than the u...

The ASCO Post